DE69513395T2 - Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden - Google Patents
Zellulare abgabesystem mit cyclodextrin, für oligonukleotidenInfo
- Publication number
- DE69513395T2 DE69513395T2 DE69513395T DE69513395T DE69513395T2 DE 69513395 T2 DE69513395 T2 DE 69513395T2 DE 69513395 T DE69513395 T DE 69513395T DE 69513395 T DE69513395 T DE 69513395T DE 69513395 T2 DE69513395 T2 DE 69513395T2
- Authority
- DE
- Germany
- Prior art keywords
- cyclodextrin
- oligonucleotides
- oligonucleotide
- delivery system
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 6
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000001413 cellular effect Effects 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 abstract 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 230000004700 cellular uptake Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25207294A | 1994-06-01 | 1994-06-01 | |
PCT/US1995/006916 WO1995032739A1 (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cellular delivery system for oligonucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69513395D1 DE69513395D1 (de) | 1999-12-23 |
DE69513395T2 true DE69513395T2 (de) | 2000-07-27 |
Family
ID=22954476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69513395T Expired - Fee Related DE69513395T2 (de) | 1994-06-01 | 1995-06-01 | Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden |
Country Status (12)
Country | Link |
---|---|
US (3) | US5691316A (de) |
EP (1) | EP0762898B1 (de) |
JP (1) | JPH10501237A (de) |
CN (1) | CN1158088A (de) |
AT (1) | ATE186647T1 (de) |
AU (1) | AU2764395A (de) |
CA (1) | CA2191777A1 (de) |
DE (1) | DE69513395T2 (de) |
DK (1) | DK0762898T3 (de) |
ES (1) | ES2139904T3 (de) |
GR (1) | GR3032355T3 (de) |
WO (1) | WO1995032739A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030099959A1 (en) * | 1995-04-12 | 2003-05-29 | Kandimalla Ekambar R. | Cooperative oligonucleotides |
US6667293B1 (en) | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
WO1999041403A1 (en) * | 1998-02-12 | 1999-08-19 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
US6716589B2 (en) | 2000-11-20 | 2004-04-06 | Alphabeta Ab | Discordant helix stabilization for prevention of amyloid formation |
TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
US20060199778A1 (en) * | 2001-09-19 | 2006-09-07 | Rutledge Ellis-Behnke | Methods and products related to non-viral transfection |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
IL161733A0 (en) * | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
CA2428740A1 (en) * | 2002-05-20 | 2003-11-20 | Bayer Corporation | Automated method and reagent therefor for assaying body fluid samples such as cerebrospinal fluid (csf) |
KR20120104412A (ko) | 2002-09-06 | 2012-09-20 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
EP1549269A4 (de) * | 2002-10-09 | 2010-10-06 | Cerulean Pharma Inc | Materialien auf cyclodextrin-basis, zusammensetzungen und ihre verwendung |
US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20050147584A1 (en) * | 2004-01-05 | 2005-07-07 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
EP1605978B1 (de) * | 2003-03-07 | 2010-09-01 | Alnylam Pharmaceuticals Inc. | Therapeutische zusammensetzungen |
US20070179100A1 (en) * | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
EP2669377A3 (de) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modifizierte iRNA-Wirkstoffe |
EP1625138A4 (de) | 2003-04-17 | 2010-06-23 | Alnylam Pharmaceuticals Inc | Geschützte monomere |
CA2542232A1 (en) | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals, Inc. | Method for treating neurodegenerative disease by inhibiting alpha-synuclein |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
US7883688B2 (en) * | 2005-02-03 | 2011-02-08 | Agency For Science, Technology And Research | Polycationic polyrotaxanes capable of forming complexes with nucleic acids |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
US20090176729A1 (en) * | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
AU2009273878A1 (en) * | 2008-07-25 | 2010-01-28 | Alnylam Pharmaceuticals, Inc. | Enhancement of siRNA silencing activity using universal bases or mismatches in the sense strand |
US20100056612A1 (en) * | 2008-08-06 | 2010-03-04 | Alexander Chucholowski | Molecular entities for binding, stabilization and cellular delivery of charged molecules |
WO2010066908A1 (en) * | 2008-12-12 | 2010-06-17 | Eurogentec S.A. | Use of cyclodextrins to improve the specificity, sensitivity and yield of nucleic acid amplification reactions |
WO2010088282A1 (en) * | 2009-01-30 | 2010-08-05 | Rgo Biosciences Llc | Nucleic acid binding assays |
CN102781237A (zh) * | 2009-11-23 | 2012-11-14 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
US20110218156A1 (en) * | 2010-02-04 | 2011-09-08 | Alexander Chucholowski | Molecular entities for binding, stabilization and cellular delivery of negatively charged molecules |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
EP2683410A2 (de) | 2011-03-08 | 2014-01-15 | Access Pharmaceuticals, Inc. | Gezielte nanocarrier-systeme zur freisetzung von wirkstoffen durch biologische membranen |
GB201216387D0 (en) | 2012-09-13 | 2012-10-31 | Ge Healthcare Uk Ltd | Solid matrix for one step nucleic acid amplification |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
KR101465365B1 (ko) * | 2013-10-15 | 2014-11-25 | 성균관대학교산학협력단 | 리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법 |
US10781175B2 (en) | 2016-07-15 | 2020-09-22 | Am Chemicals Llc | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US20190177800A1 (en) * | 2017-12-08 | 2019-06-13 | 10X Genomics, Inc. | Methods and compositions for labeling cells |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP3802819A1 (de) * | 2018-05-30 | 2021-04-14 | AXOLABS GmbH | Verfahren zum nachweis von oligonukleotidkonjugaten |
CN114874358B (zh) * | 2022-04-11 | 2023-05-02 | 上海师范大学 | 一种多核铈纳米材料的合成方法及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
IE75688B1 (en) * | 1988-07-07 | 1997-09-10 | Univ Pennsylvania | Method of modulating virus-host cell interactions using carbohydrates and carbohydrate derivatives |
WO1991002040A1 (en) * | 1989-08-04 | 1991-02-21 | Kosak Kenneth M | Cyclodextrin labels for nucleic acid and biochemical analysis |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
JPH05170650A (ja) * | 1991-12-19 | 1993-07-09 | Sanyo Kokusaku Pulp Co Ltd | 医薬組成物およびその製造方法 |
WO1993023570A1 (en) * | 1992-05-11 | 1993-11-25 | Pharmagenics, Inc. | Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety |
US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
US5457187A (en) * | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
-
1994
- 1994-11-17 US US08/341,522 patent/US5691316A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 DK DK95922923T patent/DK0762898T3/da active
- 1995-06-01 WO PCT/US1995/006916 patent/WO1995032739A1/en active IP Right Grant
- 1995-06-01 CA CA002191777A patent/CA2191777A1/en not_active Abandoned
- 1995-06-01 CN CN95194366A patent/CN1158088A/zh active Pending
- 1995-06-01 AT AT95922923T patent/ATE186647T1/de not_active IP Right Cessation
- 1995-06-01 DE DE69513395T patent/DE69513395T2/de not_active Expired - Fee Related
- 1995-06-01 EP EP95922923A patent/EP0762898B1/de not_active Expired - Lifetime
- 1995-06-01 ES ES95922923T patent/ES2139904T3/es not_active Expired - Lifetime
- 1995-06-01 AU AU27643/95A patent/AU2764395A/en not_active Abandoned
- 1995-06-01 JP JP8501182A patent/JPH10501237A/ja not_active Withdrawn
- 1995-06-07 US US08/480,834 patent/US5616565A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,833 patent/US5605890A/en not_active Expired - Lifetime
-
2000
- 2000-01-13 GR GR20000400052T patent/GR3032355T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE186647T1 (de) | 1999-12-15 |
US5691316A (en) | 1997-11-25 |
AU2764395A (en) | 1995-12-21 |
US5605890A (en) | 1997-02-25 |
JPH10501237A (ja) | 1998-02-03 |
CN1158088A (zh) | 1997-08-27 |
US5616565A (en) | 1997-04-01 |
EP0762898A1 (de) | 1997-03-19 |
WO1995032739A1 (en) | 1995-12-07 |
DE69513395D1 (de) | 1999-12-23 |
EP0762898B1 (de) | 1999-11-17 |
GR3032355T3 (en) | 2000-04-27 |
CA2191777A1 (en) | 1995-12-07 |
ES2139904T3 (es) | 2000-02-16 |
DK0762898T3 (da) | 2000-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE186647T1 (de) | Zellulare abgabesystem mit cyclodextrin, für oligonukleotiden | |
DE69835201D1 (en) | Neoglycoproteine | |
ATE494010T1 (de) | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung | |
ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
DE69906977D1 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
ATE263579T1 (de) | Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel | |
ATE156517T1 (de) | Antisens-oligonukleotide zur behandlung von krebs | |
CY1113984T1 (el) | Προϊοντα συζευξης μεϋτανσινοειδους dm1 με αντισωμα trastuzumab, συνδεδεμενα μεσω μη-διασπασιμου συνδετηρα και χρηση αυτων στη θεραπεια ογκων | |
BRPI0012196B8 (pt) | artigo industrializado | |
DE69837613D1 (de) | J-kette und analoge für konjugate zielgerichtet auf epithelzellen | |
CY1109437T1 (el) | ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ | |
NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
MXPA03004680A (es) | Materiales antimicrobianos estabilizados con respecto a la luz. | |
CY1110590T1 (el) | Επιλεκτικος ως προς την αλληλουχια dna-ανασυνδυασμος σε ευκαρυωτικα κυτταρα | |
EP1362127A4 (de) | Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung | |
TR199901949T2 (xx) | Lemfositik t�m�rler i�in �areler. | |
MY134896A (en) | Therapeutic agent for hepatitis | |
DK0841912T3 (da) | 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning | |
PT768886E (pt) | Efeitos de revestimento endotelial e tratamento de desordens vasospasticas | |
ATE396742T1 (de) | Komplexe mit adjuvanter wirkung | |
AU2668400A (en) | Human antibiotic proteins | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
ATE317263T1 (de) | Diphosphonat derivate von therapeutisch wirksamen stoffen | |
MY118864A (en) | Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer | |
EP1414299A4 (de) | Im wesentlichen homogenes, biologisch beeinflussendes material mit einem vorbestimmten verhältnis von biologisch beeinflussender komponente zu zell-targeting-komponente, verfahren zur herstellung eines solchen materials und anwendungsverfahren dafür |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |